Doximity Doubles Overnight: Squeeze or Re-Rating? Why the Difference Decides Everything

The same premarket session that saw Hertz fading from its highs had a second, bigger story: Doximity — a profitable healthcare-software company — nearly doubled before the open on volume that exceeded half a normal full day, hours after reporting earnings. Two giant movers, one morning, and the reflex take lumped them together as "squeezes." They were opposite phenomena, and telling them apart is this course's whole point.

On the surface, the report looked modest: revenue slightly ahead of expectations, profit guidance actually trimmed. The double came from what the raise was made of: every new dollar of full-year revenue guidance came from a months-old AI product — with management disclosing it earns roughly ten times what it costs to run per use, and with most of the contracted revenue not yet recognized. Investors weren't paying for this quarter; they re-valued the company's future. That's a re-rating.

The headline buried a real bear case, all from the same public filings: costs growing far faster than revenue, stock-based compensation jumping as a share of revenue, a tax-rate surprise cutting reported earnings, and next-quarter guidance implying growth of roughly one percent. The re-rating is a bet that the new product line outruns all of that. Maybe it does — but a doubled price now requires it.

Unlike Hertz, Doximity carried genuinely squeezable positioning: a meaningful fraction of its float sold short with several days needed to cover at normal volume, and no convertible-hedge asterisk. That's real fuel — as an amplifier. Shorts covering into a gap adds thrust, but the engine was the guidance composition. Getting the ordering right decides what you watch next: covering pressure exhausts in days; a re-rating is falsified (or confirmed) by the next quarter's delivery.

The practical test, in one line each: What made the move? (new narrative vs forced buying) · What kills it? (missed delivery vs exhausted covering) · What's the honest instrument? (patient equity sized as a fundamental bet vs no chase at all). Both answers that morning were "don't buy the weeklies" — Hertz because the squeeze had no fuel, Doximity because a morning-after option is a bet on an immediate second leg at peak volatility premium, not a bet on the story. Same conclusion, opposite reasoning — and the reasoning is what transfers to the next name.